Top Industry Leaders in the Transthyretin Amyloidosis Market
Latest Transthyretin Amyloidosis Companies Updates
BioMarin Pharmaceutical releases promising early data from a Phase 2 clinical trial of BMN-351, a novel investigational therapy aiming to address the underlying cause of ATTR by correcting the defective sodium chloride cotransporter.
Horizon Therapeutics receives FDA approval for Krystexxa® (burokalifex) extended-release tablets for treating hypokalemia (low potassium levels), a common symptom in ATTR
List of Transthyretin Amyloidosis Key companies in the market:
- Prothena Corporation plc.
-
Pfizer Inc. - Ionis Pharmaceuticals Inc.
- Valeant Pharmaceuticals International Inc.
- Celgene Corporation
- Takeda Pharmaceutical Company Ltd.
- Johnson and Johnson Pvt. Ltd.
- GlaxoSmithKline plc
- Alnylam Pharmaceuticals Inc.